Keywords: کارسینوم سلولهای متاستاتیک کلیه; Kidney cancer; Metastatic renal cell carcinoma; Non-clear cell renal cell carcinoma; SEER database; Racial disparities;
مقالات ISI کارسینوم سلولهای متاستاتیک کلیه (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: کارسینوم سلولهای متاستاتیک کلیه; Metastatic renal cell carcinoma; Partial nephrectomy; SEER program; Nationwide inpatient sample; Cancer-specific mortality; Other-cause mortality;
Keywords: کارسینوم سلولهای متاستاتیک کلیه; Cytoreductive nephrectomy; Lymphadenectomy; Lymph node dissection; Metastatic renal cell carcinoma; Node density;
Keywords: کارسینوم سلولهای متاستاتیک کلیه; Tivozanib; Sorafenib; First-line therapy; Metastatic renal cell carcinoma;
Keywords: کارسینوم سلولهای متاستاتیک کلیه; Renal cell carcinoma; Percutaneous biopsy; Metastatic renal cell carcinoma; Lymph node dissection;
Keywords: کارسینوم سلولهای متاستاتیک کلیه; Metastatic renal cell carcinoma; Third line therapy; Targeted therapy;
Keywords: کارسینوم سلولهای متاستاتیک کلیه; Morphometry; sarcopenia; interleukin-2; metastatic renal cell carcinoma; response prediction;
Keywords: کارسینوم سلولهای متاستاتیک کلیه; Metastatic renal cell carcinoma; Target therapy; Quality of life; Patient-reported outcomes; Clinical benefit; Randomized clinical trials;
Keywords: کارسینوم سلولهای متاستاتیک کلیه; Heterogeneity; Intermediate prognosis; Metastatic renal cell carcinoma; Sunitinib;
Keywords: کارسینوم سلولهای متاستاتیک کلیه; ccRCC; Metastatic renal cell carcinoma; NSCLC; Pulmonary nodule; Second primary tumor;
Keywords: کارسینوم سلولهای متاستاتیک کلیه; neoplasm metastasis; carcinoma; renal cell; metastasectomy; CM; complete surgical metastasectomy; GRADE; Grading of Recommendations, Assessment, Development and Evaluation; mRCC; metastatic renal cell carcinoma; no-CM; incomplete or no surgical metastasec
Keywords: کارسینوم سلولهای متاستاتیک کلیه; Collecting duct carcinoma; Metastatic renal cell carcinoma; Nivolumab; Non-clear cell renal cell carcinoma; PD1 inhibitor;
Keywords: کارسینوم سلولهای متاستاتیک کلیه; Adverse events; First-line; Metastatic renal cell carcinoma; Second-line; Tyrosine kinase inhibitors;
Keywords: کارسینوم سلولهای متاستاتیک کلیه; Metastatic Renal Cell Carcinoma; Metformin; Outcome; Sunitinib;
Keywords: کارسینوم سلولهای متاستاتیک کلیه; Metastatic renal cell carcinoma; Clear cell renal cell carcinoma; Non-clear cell renal cell carcinoma; Precision medicine; Personalized medicine; Targeted therapy; TKI; mTOR; PD-1; PD-L1
Keywords: کارسینوم سلولهای متاستاتیک کلیه; Metastatic renal cell carcinoma; Circulating biomarkers; Circulating tumor cells; Circulating tumor DNA; VEGF therapies; Immunotherapy;
Keywords: کارسینوم سلولهای متاستاتیک کلیه; AM; adrenomedullin; AMF; autocrine motility factor; AML; acute myeloid leukemia; BCL; B-cell lymphoma; BCR; breakpoint cluster region; BM; bone marrow; CCL; chemokine (CâC motif) ligand; CML; chronic myeloid leukemia; ECM; extracellular matrix; EGF; epi
Keywords: کارسینوم سلولهای متاستاتیک کلیه; kidney; carcinoma; renal cell; neoplasm metastasis; nomograms; prognosis; CCF; Cleveland Clinic Foundation; C-index; concordance index; ECOG; Eastern Cooperative Oncology Group; IMDC; International Metastatic Renal Cell Carcinoma Database Consortium; IRTL
Keywords: کارسینوم سلولهای متاستاتیک کلیه; Renal insufficiency; Metastatic renal cell carcinoma; Sunitinib;
Keywords: کارسینوم سلولهای متاستاتیک کلیه; Renal cell carcinoma; Metastatic renal cell carcinoma; Hepatectomy
CXCR1 expression predicts benefit from tyrosine kinase inhibitors therapy in patients with metastatic renal cell carcinoma
Keywords: کارسینوم سلولهای متاستاتیک کلیه; Metastatic renal cell carcinoma; CXCR1; Tyrosine kinase inhibitors; Prognosis; Therapeutic response;
Overall survival in patients with metastatic renal cell carcinoma and clinical N1 disease undergoing cytoreductive nephrectomy and lymph node dissection
Keywords: کارسینوم سلولهای متاستاتیک کلیه; Metastatic renal cell carcinoma; Cytoreductive nephrectomy; Lymph node dissection;
Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program
Keywords: کارسینوم سلولهای متاستاتیک کلیه; c-Met; Metastatic renal cell carcinoma; METEOR study; Targeted therapy; VEGF inhibitor;
Nivolumab and ipilimumab in the treatment of metastatic renal cell carcinoma. Report of two patients
Keywords: کارسینوم سلولهای متاستاتیک کلیه; Immunotherapy; Metastatic renal cell carcinoma; Nivolumab; Ipilimumab;
Hypoxia-inducing factor (HIF)-1α-derived peptide capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24+ patients with renal cell carcinoma
Keywords: کارسینوم سلولهای متاستاتیک کلیه; HIFs; hypoxia-inducing factors; RCC; renal cell carcinoma; VHL; von Hippel-Lindau; CTLs; cytotoxic T lymphocytes; mRCC; metastatic renal cell carcinoma; IL; interleukin; IFN; interferon; PD-1; programmed cell death-1; PD-L1; PD-ligand-1; CTLA-4; cytotoxic
Temsirolimus induced structural transition of cancerous renal cystatin to normal form in rats: In vitro mechanistic approach underlying renal cancer prevention
Keywords: کارسینوم سلولهای متاستاتیک کلیه; FTIR; Fourier transformed infrared spectroscopy; RKC; rat kidney cystatin; CRKC; cancerous rat kidney cystatin; CD; circular dichroism; DMN; dimethylnitrosamine; RCC; renal cell carcinoma; mRCC; metastatic renal cell carcinoma; mTOR; mechanistic target of
Clinical TrialReal world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre
Keywords: کارسینوم سلولهای متاستاتیک کلیه; Metastatic renal cell carcinoma; Axitinib; Second or further next-line; Prospective study; Effectiveness; Safety;
Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicity
Keywords: کارسینوم سلولهای متاستاتیک کلیه; Metastatic renal cell carcinoma; Therapy response; Tyrosine kinase inhibitor; Biomarker; Transcriptomics; Genomics;
C-reactive protein is a predictor of prognosis in renal cell carcinoma patients receiving tyrosine kinase inhibitors: A meta-analysis
Keywords: کارسینوم سلولهای متاستاتیک کلیه; Metastatic renal cell carcinoma; C-reactive protein; Prognosis; Meta-analysis;
Everolimus Versus Axitinib as Second-line Therapy in Metastatic Renal Cell Carcinoma: Experience From Institut Gustave Roussy
Keywords: کارسینوم سلولهای متاستاتیک کلیه; Axitinib; Efficacy; Everolimus; Metastatic renal cell carcinoma; Second-line;
Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma-Results of the REchallenge with SUnitinib in MEtastatic RCC (RESUME) Study
Keywords: کارسینوم سلولهای متاستاتیک کلیه; First-line; Metastatic renal cell carcinoma; Rechallenge; Resistance; Sunitinib;
Étude des facteurs pronostiques pour le carcinome rénal métastatique traité par une deuxième ligne de thérapies ciblées
Keywords: کارسینوم سلولهای متاستاتیک کلیه; Facteurs pronostiques; Cancer du rein métastatique; Thérapies ciblées; Survie; Toxicité induitePrognostic factors; Metastatic renal cell carcinoma; Targeted therapies; Survival; Induced toxicity
Is sunitinib a Narrow Therapeutic Index Drug? - A systematic review and in vitro toxicology-analysis of Sunitinib vs. Imatinib in cells from different tissues
Keywords: کارسینوم سلولهای متاستاتیک کلیه; Apoptosis; Drug safety; Imatinib; Narrow Therapeutic Index Drug (NTID); Receptor tyrosine kinase (RTK); Sunitinib; Toxicity; Tyrosine kinase inhibitor (TKI); Cell viability; ALL; acute lymphoblastic leukemia; AUC; area under the curve; b.i.d.; twice daily
Prognostic Value of SETD2 Expression in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors
Keywords: کارسینوم سلولهای متاستاتیک کلیه; carcinoma; renal cell; neoplasm metastasis; survival; disease-free survival; biomarkers; ccRCC; clear cell renal cell carcinoma; IHC; immunohistochemistry; IRS; immunoreactivity score; mRCC; metastatic renal cell carcinoma; OS; overall survival; PFS; prog
Nefrectomia citorredutora pós‐sunitinib no carcinoma das células renais metastizado. A propósito de um caso clínico
Keywords: کارسینوم سلولهای متاستاتیک کلیه; Nefrectomia citorredutora; Carcinoma das células renais metastizado; Sunitinib; Sobrevida global; PrognósticoCytorreductive nephrectomy; Metastatic renal cell carcinoma; Sunitinib; Overal survival; Prognosis
The use of error-category mapping in pharmacokinetic model analysis of dynamic contrast-enhanced MRI data
Keywords: کارسینوم سلولهای متاستاتیک کلیه; PK; pharmacokinetic; DCE-MRI; dynamic contrast-enhanced magnetic resonance imaging; eTM; extended Tofts model; AIF; arterial input function; AIC; Akaike information criterion; mRCC; metastatic renal cell carcinoma; MFA; multiple flip angles; ROI; region o
Health Economic Changes as a Result of Implementation of Targeted Therapy for Metastatic Renal Cell Carcinoma: National Results from DARENCA Study 2
Keywords: کارسینوم سلولهای متاستاتیک کلیه; Cost analysis; Economic analysis; Implementation; Metastatic renal cell carcinoma; National; Population-based; Targeted therapy; Observational;
Everolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: Results of a pooled analysis of non-interventional studies
Keywords: کارسینوم سلولهای متاستاتیک کلیه; Everolimus; Metastatic renal cell carcinoma; Non-interventional; Sequential targeted therapy;
Sunitinib dosing schedule 2/1 improves tolerability, efficacy, and health-related quality of life in Chinese patients with metastatic renal cell carcinoma
Keywords: کارسینوم سلولهای متاستاتیک کلیه; Metastatic renal cell carcinoma; Sunitinib; Dosing schedules; Adverse events; Tumor response; Quality-of-life;
UNC-51-like kinase 1 expression in radical nephrectomy specimens as a predicting factor of progression-free survival in patients with metastatic renal cell carcinoma treated with mammalian target of rapamycin inhibitors
Keywords: کارسینوم سلولهای متاستاتیک کلیه; Metastatic renal cell carcinoma; Autophagy; UNC-51-like kinase 1; Mammalian target of rapamycin inhibitor;
Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: A Southern China Urology Cancer Consortium Trial
Keywords: کارسینوم سلولهای متاستاتیک کلیه; Pazopanib; Metastatic renal cell carcinoma; Phase II; Delta-like ligand 4; Hypoxia-inducible factor;
CYP3A5 and ABCB1 Polymorphisms as Predictors for Sunitinib Outcome in Metastatic Renal Cell Carcinoma
Keywords: کارسینوم سلولهای متاستاتیک کلیه; Sunitinib; Pharmacogenetics; Metastatic renal cell carcinoma; Single nucleotide polymorphism; Biomarker; Association analysis;
Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
Keywords: کارسینوم سلولهای متاستاتیک کلیه; Cytoreductive nephrectomy; Metastatic renal cell carcinoma; Targeted therapy;
Sunitinib objective response in metastatic renal cell carcinoma: Analysis of 1059 patients treated on clinical trials
Keywords: کارسینوم سلولهای متاستاتیک کلیه; Sunitinib; Objective response; Metastatic renal cell carcinoma;
Valeur pronostique de la toxicité induite par les thérapies ciblées dans le carcinome rénal métastatique
Keywords: کارسینوم سلولهای متاستاتیک کلیه; Facteurs pronostiques; Survie; Cancer du rein métastatique; Thérapies ciblées; Toxicité induite; Métastase cérébrale; Prognostic factors; Survival; Metastatic renal cell carcinoma; Targeted therapies; Induced toxicity; Brain metastasis;
Alternative dosing schedules for sunitinib as a treatment of patients with metastatic renal cell carcinoma
Keywords: کارسینوم سلولهای متاستاتیک کلیه; Alternative schedule; Metastatic renal cell carcinoma; Sunitinib; Two weeks on/one week off.
Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: Results from the Danish Renal Cancer Group (DARENCA) study-2
Keywords: کارسینوم سلولهای متاستاتیک کلیه; Metastatic renal cell carcinoma; National cohort; Overall survival; Targeted therapy; Population-based study;
Axitinib dans le cancer du rein métastatique: actualisation des connaissances sur la prise en charge des effets secondaires
Keywords: کارسینوم سلولهای متاستاتیک کلیه; axitinib; cancer du rein métastatique; effets secondaires; inhibiteurs de tyrosine kinase; recommandations; axitinib; metastatic renal cell carcinoma; side effects; tyrosine kinase inhibitors; recommendations;
A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma
Keywords: کارسینوم سلولهای متاستاتیک کلیه; Vascular endothelial growth factor-targeted therapy; Systematic review; Metastatic renal cell carcinoma; Biomarkers
Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients
Keywords: کارسینوم سلولهای متاستاتیک کلیه; Targeted therapy; Second line; Metastatic renal cell carcinoma;